| Literature DB >> 32940881 |
Andreas Ihrig1, I Maatouk2, H C Friederich2, M Baunacke3, C Groeben3, R Koch3, C Thomas3, J Huber3.
Abstract
Different patients want to take different roles in the treatment decision-making process; these roles can be classified as passive, collaborative, and active. The aim of this study was to investigate the correlation between decision-making preferences among patients with prostate cancer and personal, disease-related, and structural factors. In four survey studies, we asked 7169 prostate cancer patients about their decision-making preferences using the Control Preferences Scale (CPS) and collected clinical, psychological, and quality-of-life measures. Most patients (62.2%) preferred collaborative decision-making, while 2322 (32.4%) preferred an active role, and only 391 (5.5%) preferred a passive role. Age (p < 0.001), data collection mode (p < 0.001), peer-to-peer support (p = 0.018), treatment status (p < 0.001), performed or planned radical prostatectomy (p < 0.001), metastatic disease (p = 0.001), and quality of life (p < 0.001) showed significant associations with patients' preferred decision-making roles. Oncologic risk group, anxiety, and depression were not significant in the model. In particular, younger prostate cancer patients with higher quality of life completing an online survey want to play a more active role in treatment decision-making. Before treatment has started, patients tend to prefer collaborative decision-making. Few prostate cancer patients in Germany prefer a passive role. These patients are mostly older patients, patients with a metastatic disease, and patients who have opted for prostatectomy. Whether this finding reflects a generational effect or a tendency by age group and disease phase should be investigated. Further research is also needed to describe the causalities of these relationships. The CPS offers valuable information for personal counselling and should be applied in clinical routine. In a large group of patients with prostate cancer, we found that there is a strong desire for joint decision-making with the physician before the actual treatment. Especially younger men, men with active online behaviour, and men with a high quality of life want to be actively involved in therapy decision-making processes.Entities:
Keywords: Health services research; Prostate cancer; Treatment decision-making
Mesh:
Year: 2020 PMID: 32940881 PMCID: PMC9205804 DOI: 10.1007/s13187-020-01867-2
Source DB: PubMed Journal: J Cancer Educ ISSN: 0885-8195 Impact factor: 1.771
Results of the Control Preferences Scale
| All | Data collection mode | ||||
|---|---|---|---|---|---|
| Online, | Paper and pencil, | ||||
| Active | I prefer to make the final treatment selection | 172 (2.4%) | 113 (2.0%) | 59 (3.6%) | < 0.001 |
| I prefer to make the final treatment selection after seriously considering my doctor’s opinion | 2150 (30.0%) | 1698 (30.7%) | 452 (27.6%) | ||
| Collaborative | I prefer that my doctor and I share responsibility for deciding which treatment is best | 4456 (62.2%) | 3484 (63.0%) | 972 (59.3%) | |
| Passive | I prefer my doctor to make the final treatment decision, but only after my doctor has seriously considered my opinion | 342 (4.8%) | 227 (4.1%) | 115 (7.0%) | |
| I prefer to leave all treatment decisions to my doctor | 49 (0.7%) | 8 (0.1%) | 41 (2.5%) | ||
Comparison of medical data, age, quality of life, depression, and anxiety in the different control preference groups
| Active, | Collaborative, | Passive, | ||
|---|---|---|---|---|
| Age | ||||
| <51 | 77 (3.3%) | 76 (1.7%) | 6 (1.5%) | < 0.001a |
| 51–60 | 467 (20.1%) | 754 (17.0%) | 59 (15.1%) | |
| 61–70 | 1007 (43.4%) | 1902 (42.8%) | 148 (37.9%) | |
| > 70 | 769 (33.1%) | 1716 (38.6%) | 178 (45.5%) | |
| Education* | ||||
| Low | 448 (23.4%) | 1050 (29.1%) | 76 (29.6%) | |
| Medium | 510 (26.7%) | 1078 (29.9%) | 68 (26.5%) | < 0.001c |
| High | 754 (39.4%) | 1152 (31.9%) | 85 (33.1%) | |
| Peer-to-peer support | ||||
| Self-help users | 716 (30.8%) | 867 (19.5%) | 67 (17.1%) | < 0.001c |
| None | 1606 (69.2%) | 3589 (80.5%) | 324 (82.9%) | |
| Treatment status | ||||
| Before treatment | 1334 (57.5%) | 3075 (69.0%) | 215 (55.0%) | < 0.001c |
| After treatment | 988 (42.5%) | 1381 (31.0%) | 176 (45.0%) | |
| Radical prostatectomy | ||||
| Performed/planned | 1603 (69.0%) | 3245 (72.8%) | 317 (81.1%) | < 0.001c |
| None | 719 (31.0%) | 1211 (27.2%) | 74 (18.9%) | |
| Gleason score | ||||
| ≤ 6 | 859 (39.6%) | 1468 (35.3%) | 111 (31.1%) | |
| 7 | 1029 (47.5%) | 2036 (48.9%) | 179 (50.1%) | < 0.001k |
| ≥ 8 | 279 (12.9%) | 656 (15.8%) | 67 (18.8%) | |
| Metastatic disease | ||||
| M0/Mx | 2101 (32.3%) | 4059 (62.4%) | 340 (5.2%) | 0.10c |
| M1 | 92 (34.5%) | 154 (57.7%) | 21 (7.9%) | |
| Risk group | ||||
| Low | 648 (29.5%) | 1094 (25.9%) | 86 (23.5%) | |
| Intermediate | 866 (39.4%) | 1734 (41.1%) | 143 (39.1%) | 0.003k |
| High | 684 (31.1%) | 1392 (33.0%) | 137 (37.4%) | |
| EORTC score | ||||
| ≤ 50 | 411 (17.9%) | 843 (19.1%) | 87 (22.5%) | |
| 51–75 | 665 (28.9%) | 1417 (32.1%) | 132 (34.2%) | < 0.001a |
| ≥ 76 | 1226 (53.3%) | 2158 (48.8%) | 167 (43.3%) | |
| PHQ-2 | 1.0 ± 1.3 0.5 (0–6) | 1.0 ± 1.2 1 (0–6) | 1.1 ± 1.4 1 (0–6) | 0.14a |
| GAD-2 | 1.0 ± 1.3 1 (0–6) | 1.0 ± 1.2 1 (0–6) | 1.1 ± 1.4 1 (0–6) | 0.056a |
*Education was not assessed in the HAROW survey
aAnalysis of variance
cChi-square test
kKruskal-Wallis test
Fig. 1Significant variables of the common slopes cumulative logit model (N = 6703)
Results of decision-making preferences based on the CPS in studies with prostate cancer patients
| Authors and year | Population | Preferred decision-making role | ||
|---|---|---|---|---|
| Active (%) | Collaborative (%) | Passive (%) | ||
| Davison, Degner et al. 1995 | 57 Canadian prostate cancer patients | 19 | 23 | 58 |
| Davison, Gleave et al. 2002 | 80 Canadian prostate cancer patients | 50 | 43 | 8 |
| Davison, Parker et al. 2004 | 87 Canadian transrectal biopsy patients | 43 | 47 | 10 |
| Cuypers, Lamers et al. 2016 | 562 prostate cancer patients from the Netherlands | 22 | 59 | 19 |
| Drummond, Gavin et al. 2018 | 3348 prostate cancer survivors in Ireland | 36 | 33 | 31 |
| Ihrig, Maatouk et al. 2020 | 7169 German prostate cancer patients (pooled analysis) | 32 | 62 | 6 |